Abstract:Background Pregnancy is associated with physiological changes that can alter the pharmacokinetic and pharmacodynamic profile of many drugs. Low-dose aspirin is used for pre-eclampsia (PE) prevention; however aspirin's pharmacokinetics and pharmacodynamics are poorly studied in pregnant women. Objective The aim of this study was to compare the pharmacodynamics of two common doses of aspirin (75 and 150 mg) used for PE prevention in high-risk women by examining their effect on thromboxane B 2 (TbxB 2 ) inhibition. A secondary objective sought to assess if salicylic acid could be used as means to evaluate adherence to aspirin. Study Design Fourteen pregnant women from a large maternity unit in England, eligible for prophylactic aspirin according to NICE guidance, were recruited into 2 x 2 randomised crossover trial. Blood samples were collected at baseline, 1, 2, 3, 4, 15, 16, 17, 18 and 19-hours post ingestion of either 75 or 150 mg of aspirin with a 7-day washout period. Plasma concentrations of salicylic acid (SA), the primary metabolite of aspirin, were determined using high performance liquid chromatography. Pharmacodynamic response to aspirin was assessed by measuring serum thromboxane B 2 (TbxB 2 ) concentrations by an enzyme-linked immunosorbent assay. Analyte data were compared using nonparametric test statistics for paired values (Wilcoxon Signed Rank Test) and areas under serum SA concentration versus time curve (AUC). Pharmacokinetic modelling was used to bridge the data arising from the overnight sampling break.The trial was registered with the ISRCTN (reg number ISRCTN14693054). Results A single dose of 150 mg of aspirin produced higher plasma exposure of SA in comparison to 75 mg (median SA AUC 0-19 16.7 μg*h/ml (IQR 15.2-19.3) vs 6.8 μg*h/ml (IQR 6.1- 8.3), p<0.001). Pharmacokinetic models suggest that plasma SA concentrations could be detected above the maximum concentration recorded at baseline for the first 11 hours after 75 mg and for 12 hours after 150 mg aspirin dosing, providing a time frame to confirm recent aspirin ingestion. The 150 mg aspirin dose produced a greater normalised reduction in serum TbxB 2 (median normalised reduction 95.7% (IQR 92.6%- 97.3%) than the 75 mg dose (median normalised reduction 84.6% (IQR 77.3-92.3%), p<0.007. Conclusion Compared to the 75 mg dose, 150 mg of aspirin more effectively inhibits TbxB 2 , providing rationale for further investigation of effectiveness of higher doses for pre-eclampsia prevention. Despite limitations, measuring serum SA concentration could still be used in future models to test adherence if done within 11-12 hours after ingestion.

OC01.03: Uterine artery vasodilation and its impact on maternal and perinatal outcomes in aspirin‐using pregnant women for preterm pre‐eclampsia prevention

OC01.02: *Effect of aspirin on placental biomarkers profile in high‐risk women for pre‐eclampsia

ASPRE trial: effects of aspirin on mean arterial blood pressure and uterine artery pulsatility index trajectories in pregnancy

OC16.06: Fetal and neonatal events associated with low‐dose aspirin during the first trimester of pregnancy: secondary analysis of the ASPIRIN trial

Mid-trimester uterine artery Doppler for aspirin discontinuation in pregnancies at high risk for preterm pre-eclampsia: Post-hoc analysis of StopPRE trial

OP13.01: *Effective aspirin treatment for women at risk of pre‐eclampsia delays the metabolic clock of gestation

Effect of aspirin on uterine hemodynamics in patients with early recurrent spontaneous abortion

P182 AORTIC VASCULAR BIOMARKERS FOR THE EARLY DETECTION OF PLACENTAL SYNDROMES DURING PREGNANCY: A SYSTEMATIC REVIEW AND META-ANALYSIS

Low-dose Aspirin for Primary Prevention of Adverse Pregnancy Outcomes in Twin Pregnancies: an Observational Cohort Study Based on Propensity Score Matching

OC02.08: *Effect of Mediterranean diet or stress reduction interventions during pregnancy on placental volume and perfusion: IMPACT BCN trial sub‐analysis

A randomised crossover design study comparing the pharmacokinetics and pharmacodynamics of two single Doses of ORal Aspirin (75 mg v 150mg) in pregnant women at risk of pre-eclampsia (DORA): implications on assessing aspirin response and patient adherence to therapy.

Comparison of Utero-Placental Perfusion Development From First to Second Trimester Between Low-Risk and High-Risk Pre-eclampsia Groups With Aspirin Prophylaxis

OC17.06: *First trimester cardiac function in women with and without high risk of pre‐eclampsia

Effects of Low-Dose Aspirin on the Prevention of Preeclampsia and Pregnancy Outcomes: A Randomized Controlled Trial from Shanghai, China.

EP17.42: Association between mean arterial pressure and uterine artery pulsatility index >95th percentile in first trimester screening in singleton pregnancies

EP08.54: Uterine arteries pulsatility index in the second trimester of pregnancy as a predictor of fetal intrauterine growth restriction

Short-term effects of first trimester low-dose aspirin therapy on uterine artery flow in women at high risk for preeclampsia

Clinical and sonographic risk factors for developing pre-eclampsia refractory to aspirin prophylaxis

EP17.75: Investigation of uterine artery pulsatility index in pregnant women with spontaneous preterm labour

Aspirin for the prevention and treatment of pre-eclampsia: A matter of COX-1 and/or COX-2 inhibition?

Aspirin for the prevention of preeclampsia: A systematic review and meta-analysis of randomized controlled studies